Abstract
Fibroblast growth factor receptors (FGFR) are members of a family of polypeptides synthesized by a variety of cell types during the processes of embryonic development and in adult tissues. FGFR have been detected in normal and malignant cells and are involved in biological events that include mitogenic and angiogenic activity with a consequent crucial role in cell differentiation and development. To activate signal transduction pathways, FGFR are coupled to fibroblast growth factors (FGF) and heparan sulfate (HS) proteoglycans to form a biologically fundamental ternary complex. Based on these considerations, a variety of inhibitors able to block the signaling cascade through a direct interaction with FGFR have been designed and investigated for their biological properties related to antiangiogenesis and antitumor activity. The purpose of this review is to focus on synthetic chemical approaches aimed at blocking tyrosine kinase (TK) receptors, members of the FGFR family. In particular, a literature survey aimed at summarizing on the structural properties that a compound should possess to show affinity toward FGFR is presented, and structure-activity relationships (SAR) on FGFR inhibitors are delined.
Keywords: Fibroblast, Growth Factor Receptor, Tyrosine Kinases (TK), heparan sulfate (HS, proteoglycans
Current Pharmaceutical Design
Title: Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK)
Volume: 9 Issue: 7
Author(s): Fabrizio Manetti and Maurizio Botta
Affiliation:
Keywords: Fibroblast, Growth Factor Receptor, Tyrosine Kinases (TK), heparan sulfate (HS, proteoglycans
Abstract: Fibroblast growth factor receptors (FGFR) are members of a family of polypeptides synthesized by a variety of cell types during the processes of embryonic development and in adult tissues. FGFR have been detected in normal and malignant cells and are involved in biological events that include mitogenic and angiogenic activity with a consequent crucial role in cell differentiation and development. To activate signal transduction pathways, FGFR are coupled to fibroblast growth factors (FGF) and heparan sulfate (HS) proteoglycans to form a biologically fundamental ternary complex. Based on these considerations, a variety of inhibitors able to block the signaling cascade through a direct interaction with FGFR have been designed and investigated for their biological properties related to antiangiogenesis and antitumor activity. The purpose of this review is to focus on synthetic chemical approaches aimed at blocking tyrosine kinase (TK) receptors, members of the FGFR family. In particular, a literature survey aimed at summarizing on the structural properties that a compound should possess to show affinity toward FGFR is presented, and structure-activity relationships (SAR) on FGFR inhibitors are delined.
Export Options
About this article
Cite this article as:
Manetti Fabrizio and Botta Maurizio, Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK), Current Pharmaceutical Design 2003; 9 (7) . https://dx.doi.org/10.2174/1381612033391487
DOI https://dx.doi.org/10.2174/1381612033391487 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products
Current Drug Targets Targets of 3-Bromopyruvate, A New, Energy Depleting, Anticancer Agent
Medicinal Chemistry Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Human miR-5193 Triggers Gene Silencing in Multiple Genotypes of Hepatitis B Virus
MicroRNA Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Fibroblast Growth Factor Receptor-3 as a Therapeutic Target for Achondroplasia - Genetic Short Limbed Dwarfism
Current Drug Targets Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Combination of Multifunctional Nanoparticles and Interventional Techniques Makes Each Other Going Further in the Field of Cancer Treatment
Current Drug Metabolism Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Optimization Towards Dose Carving for Head and Neck Treatment Planning
Current Cancer Therapy Reviews 8-bromo-7-methoxychrysin Reversed M2 Polarization of Tumor-associated Macrophages Induced by Liver Cancer Stem-like Cells
Anti-Cancer Agents in Medicinal Chemistry Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets